UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
--------------------------------------------------------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 19, 2003
--------------------------
PROVECTUS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Nevada 0-9410 90-0031917
--------------------------------------------------------------------------------
(State or Other Jurisdiction of (Commission (I.R.S. Employer
Incorporation or Organization) File Number) Identification Number)
7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee 37931
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: 865/769-4011
--------------------------
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events.
On December 2, 2003, Provectus Pharmaceuticals, Inc. (the "Company")
announced that it has completed a short-term unsecured debt financing in the
aggregate gross amount of $500,000 (the "Offering"). On November 19, 2003, the
Company issued in a private placement to "accredited investors" under the
Securities Act of 1933, as amended, (i) $500,000 in the aggregate principal
amount of its 8% unsecured convertible debentures; (ii) warrants to purchase up
to 500,000 shares of the Company's common stock, $.001 par value (the "Common
Stock") at an exercise price of $1.00 per share; and (iii) warrants to purchase
up to 100,000 shares of the Company's Common Stock at an exercise price of $1.25
per share. The Company will use the proceeds of the Offering to provide
short-term working capital.
The Company issued a press release which is attached hereto as Exhibit 99.1
and incorporate herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
Exhibits required by Item 601 of Regulation S-B are incorporated herein by
reference and are listed on the attached Exhibit Index, which begins on page X-1
of this Current Report on Form 8-K.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Provectus Pharmaceuticals, Inc.
Dated: December 2, 2003 By:/s/ H. Craig Dees
------------------------------------------
H. Craig Dees
Chief Executive Officer
Exhibit Index
Exhibit No. Description
-------------- -----------
99.1 Press Release of Provectus Pharmaceuticals, Inc.